Affordable Access

Cautious welcome for antiretroviral cost reduction in South Africa.

Authors
Type
Published Article
Journal
Lancet (London, England)
Publication Date
Volume
355
Issue
9217
Pages
1799–1799
Identifiers
PMID: 10832840
Source
Medline
Keywords
License
Unknown

Abstract

South Africa has cautiously welcomed the pledge of five pharmaceutical firms (GlaxoWellcome, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, and Merck) to cut the prices of their HIV/AIDS drugs by up to 90% for African countries and other developing nations. Africa's AIDS activists are concerned that the deal will be conditional on governments undertaking not to promote the use of generic substances. In this regard South Africa¿s health minister, Mantho Tshabalala-Msimang, welcomed the decision by US President Bill Clinton to drop the threat of trade sanctions against countries planning to produce cheap generic drugs. In another development, South African Airways admitted that it had acted ¿unjustifiably¿ by excluding a job seeker who was HIV-positive. The airline agreed to pay the man R100,000 and his legal costs.

Statistics

Seen <100 times